TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00546364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2
Description: Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
Description: Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Description: Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Study: NCT02043925

Intervention type: DRUG
Intervention: drugs linked with QT-prolongation
Description: all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
Study: NCT03655834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: patients will be administered a microdose with subsequent pharmacokinetic assessment.
Study: NCT01420510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adelmidrol vaginal gel
Description: Application of a Adelmidrol vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal gel
Description: Application of a placebo vaginal gel
Study: NCT04489979

Intervention type: OTHER
Intervention: Antibiotics
Description: Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.

Intervention type: OTHER
Intervention: Antibiotics
Description: Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
Study: NCT02058732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
Study: NCT02109159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A short online video with emotional content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A short online video with less emotional content
Study: NCT00249574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Human subjects HIV, HCV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegInterferon
Description: intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
Study: NCT04041336

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Non-invasive method of acquiring cross sectional imaging of tissues using the coherent property of light
Study: NCT04051957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
Study: NCT03381456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LICI
Description: Paired pulse TMS to measure LICI and late cortical disinhibition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LICI
Description: Paired pulse TMS to measure LICI and late cortical disinhibition
Study: NCT02753010

Intervention type: PROCEDURE
Intervention: Gastric emptying of carbohydrate-rich beverage
Description: Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.

Intervention type: PROCEDURE
Intervention: Gastric emptying of carbohydrate-rich beverage
Description: Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..

Intervention type: PROCEDURE
Intervention: Gastric emptying of carbohydrate-rich beverage
Description: Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
Study: NCT02307916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-2
Description: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator using a sterile saline solution.
Study: NCT01081756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hCG
Description: r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary-hCG
Description: Urinary hCG (10,000 IU) injection s.c. or i.m.
Study: NCT03817203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape application
Description: Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tape application
Description: Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
Study: NCT03261323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast-Q questionnaire
Description: Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast-Q questionnaire
Description: Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
Study: NCT01977885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: All participants will be individually counseled by an RD for \~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or \~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
Study: NCT02186184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle
Study: NCT03064672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcervical Balloon Catheters
Description: induction of labor by transcervical Balloon Catheters insertion
Study: NCT02813122

Intervention type: DEVICE
Intervention: x-ray
Description: x-ray for the detection of leaks and bleeding
Study: NCT01307033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0954A
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-954H
Description: Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-0954A
Description: Placebo tablet to match MK-0954A, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-954H
Description: Placebo tablet to match MK-954H, once daily
Study: NCT00570648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: 1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
Study: NCT00555087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate and/or PDE-5
Description: Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
Study: NCT02553694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced education
Description: Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced education
Description: Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual education
Description: Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual education
Description: Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual follow up
Description: MD will follow up by phone after the in-laboratory split night polysomnogram

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual follow up
Description: MD will follow up by phone after the in-laboratory split night polysomnogram

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced follow up
Description: Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced follow up
Description: Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
Study: NCT01934140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 1 dose administered intramuscularly in the non-dominant deltoid region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: 1 dose administered intramuscularly in the non-dominant deltoid region.
Study: NCT03658226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Interpersonal Therapy (PIT)
Description: PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
Study: NCT01831128

Intervention type: DEVICE
Intervention: ASV Treatment
Study: NCT01098890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: 2mg tPA will be given every twelve hours for a maximum of 5 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 12 hours for a maximum of 5 doses.
Study: NCT00947531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Study: NCT02312804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily on each day of the 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily on each day of the 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
Study: NCT01050114

Intervention type: DRUG
Group type: OTHER
Intervention: onaBoNT-A
Description: onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxybutynin ER
Description: Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
Study: NCT04223245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise+multi-modal sensory feedback (MMSF)
Description: home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
Study: NCT04773886

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Biodentine
Description: Vital Pulpotomy will be done using Biodentine as pulp capping agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: Vital Pulpotomy will be done using Biodentine as pulp capping agent

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: 10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: 10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece
Study: NCT02351596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Core Stability Group Programme
Description: The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Core Stability Group Programme
Description: The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this.
Study: NCT04223245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: 3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
Study: NCT02351596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
Study: NCT03743831

Intervention type: DEVICE
Group type: OTHER
Intervention: orotracheal intubation by direct laryngoscopy
Description: Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch

Intervention type: DEVICE
Group type: OTHER
Intervention: orotracheal intubation by indirect laryngoscopy
Description: orotracheal intubation by indirect laryngoscopy by Airtraq